Success Story: 17-Day NIW Approval! Indian Lab Specialist Achieves Success with Our Expert’s Strategy and Premium Processing
Client’s Testimonial:
“Great News. I really appreciate your support and guidance throughout the I-140 NIW process.”
On March 10th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Lab Specialist Senior in the Field of Radiopharmaceutical Medicinal Chemistry (Approval Notice).
General Field: Radiopharmaceutical Medicinal Chemistry
Position at the Time of Case Filing: Lab Specialist Senior
Country of Origin: India
State of Residence at the Time of Filing: Virginia
Approval Notice Date: March 10th, 2025
Processing Time: 17 days (Premium Processing Requested)
Case Summary:
At North America Immigration Law Group, we are proud to announce the successful approval of an I-140 National Interest Waiver (NIW) petition for an exceptional expert in radiopharmaceutical medicinal chemistry. The petition received a decision just after 17 days, with Direct Premium Processing at the time of filing. This achievement underscores the vital importance of their contributions to molecular imaging and therapeutic advancements.
The petitioner, who holds a Ph.D. in medicinal chemistry, is a leading expert dedicated to developing and optimizing radiotracer synthesis, formulations, and quality control methods for molecular imaging. This crucial research aims to enhance early diagnosis and targeted treatment strategies for neurodegenerative diseases and cancers, while also ensuring the safety and efficacy of radiotracers in clinical applications. Their proposed endeavor holds substantial merit and national importance by addressing the immense global health burden of cancer (over 20 million new cases annually) and the significant economic impact of neurodegenerative diseases in the United States (exceeding $655 billion annually). Their innovations enable earlier and more precise detection, leading to more effective personalized treatments.
The client is currently employed at a U.S. institution and plans to pursue employment as a radiopharmaceutical medicinal chemist in the U.S., where they will continue to develop novel radiopharmaceuticals for the diagnosis and treatment of various cancers and neurodegenerative diseases, and publish original research in their field.
To support the NIW petition, we presented compelling evidence of the researcher's distinguished contributions to the field of radiopharmaceutical medicinal chemistry:
● A strong publication record, including 14 peer-reviewed journal articles, 4 patent applications, and 6 granted patents.
● An impressive citation count of 920, demonstrating that their published work is widely recognized and relied upon by peers.
● The national importance of their research is further highlighted by its direct relevance to advancing the U.S. in critical and emerging technologies like medical imaging and biotechnology.
We are honored to have supported this gifted expert and look forward to their continued groundbreaking contributions to the diagnosis and treatment of severe diseases in the United States and globally.